Press release
Uremic Pruritus Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Sol-Gel Technologies Ltd., Krystal Biotech Inc.
Uremic Pruritus Pipeline Insight
According to DelveInsight, over two key companies are actively engaged in developing more than two treatment therapies for Uremic Pruritus, reflecting ongoing efforts to address this condition.
Uremic Pruritus Overview:
Uremic pruritus (UP), also referred to as chronic kidney disease-associated pruritus (CKD-aP), is a common and burdensome condition seen in individuals with advanced chronic kidney disease, especially those undergoing dialysis. It is marked by ongoing itching, usually without a clear skin-related cause, and can severely impact a patient's quality of life. While the exact cause remains unclear, it is thought to involve systemic inflammation, metabolic disturbances, and the buildup of uremic toxins due to reduced kidney function.
The main symptom is relentless itching, which may be generalized or localized to areas such as the back, arms, or face. Itching tends to worsen at night, leading to sleep disturbances and fatigue. Although the skin often appears normal in the early stages, prolonged scratching can cause visible damage like lesions and thickened skin. UP often coexists with other CKD-related symptoms such as dry skin and muscle cramps.
Diagnosis is based largely on clinical evaluation, considering a patient's history of CKD and persistent itching in the absence of a clear alternative explanation. Physicians typically exclude other possible causes, such as allergic reactions or dermatological diseases, through physical exams and laboratory tests. Although there is no definitive cure, treatment focuses on relieving symptoms and enhancing quality of life. Management strategies include improving dialysis efficiency to lower toxin levels, applying moisturizers for dry skin, and using medications like antihistamines or gabapentinoids to control itching. In more severe cases, systemic therapies such as opioid receptor modulators (e.g., nalfurafine), corticosteroids, and narrowband UVB phototherapy may offer additional relief.
Request for a detailed insights report on Uremic Pruritus pipeline insights @ https://www.delveinsight.com/report-store/uremic-pruritus-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
"Uremic Pruritus Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Uremic Pruritus Therapeutics Market.
Key Takeaways from the Uremic Pruritus Pipeline Report
*
DelveInsight's Uremic Pruritus pipeline report depicts a robust space with 2+ active players working to develop 2+ pipeline therapies for Uremic Pruritus treatment.
*
Key Uremic Pruritus companies such as Qilu Pharmaceutical, and others are evaluating new drugs for Uremic Pruritus to improve the treatment landscape.
*
Promising Uremic Pruritus pipeline therapies in various stages of development include QLG2198, and others.
*
Lumosa Therapeutics is developing LT5001, a topical ointment containing dinalbuphine sebacate (DNS), designed to alleviate pruritus. DNS acts as a kappa-opioid receptor agonist and mu-opioid receptor antagonist, aiming to reduce itching without significant systemic absorption. This formulation offers a convenient application for patients.
*
The U.S. Food and Drug Administration (FDA) approved difelikefalin, marketed as Korsuva, for the treatment of moderate to severe pruritus in adults undergoing hemodialysis. This approval marked the first FDA-endorsed treatment specifically targeting uremic pruritus, offering relief to patients who previously had limited options.
Uremic Pruritus Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the key companies that are developing therapies in the Uremic Pruritus Market.
*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Uremic Pruritus treatment.
*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Uremic Pruritus market.
Download our free sample page report on Uremic Pruritus pipeline insights [https://www.delveinsight.com/sample-request/uremic-pruritus-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Uremic Pruritus Emerging Drugs
*
QLG2198: Qilu Pharmaceutical
Uremic Pruritus Companies
Approximately two or more leading companies are actively developing treatments for uremic pruritus. Among them, Qilu Pharmaceutical has the most advanced drug candidates, currently in Phase III clinical trials.
DelveInsight's report covers around 2+ products under different phases of clinical development like
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I) along with the details of
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
Uremic Pruritus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Uremic Pruritus Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Uremic Pruritus Therapies and Key Companies: Uremic Pruritus Clinical Trials and advancements [https://www.delveinsight.com/report-store/uremic-pruritus-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Uremic Pruritus Pipeline Therapeutic Assessment
- Uremic Pruritus Assessment by Product Type
- Uremic Pruritus By Stage
- Uremic Pruritus Assessment by Route of Administration
- Uremic Pruritus Assessment by Molecule Type
Download Uremic Pruritus Sample report to know in detail about the Uremic Pruritus treatment market @ Uremic Pruritus Therapeutic Assessment [https://www.delveinsight.com/sample-request/uremic-pruritus-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Uremic Pruritus Current Treatment Patterns
4. Uremic Pruritus - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Uremic Pruritus Late-Stage Products (Phase-III)
7. Uremic Pruritus Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Uremic Pruritus Discontinued Products
13. Uremic Pruritus Product Profiles
14. Uremic Pruritus Key Companies
15. Uremic Pruritus Key Products
16. Dormant and Discontinued Products
17. Uremic Pruritus Unmet Needs
18. Uremic Pruritus Future Perspectives
19. Uremic Pruritus Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Uremic Pruritus Pipeline Reports Offerings [https://www.delveinsight.com/report-store/uremic-pruritus-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=uremic-pruritus-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-pipeline-analysis-solgel-technologies-ltd-krystal-biotech-inc]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Uremic Pruritus Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Sol-Gel Technologies Ltd., Krystal Biotech Inc. here
News-ID: 4132313 • Views: …
More Releases from ABNewswire
How DarioHealth Quietly Became One of the Most Intriguing Setups in Digital Heal …
TL;DR: A growing $69M pipeline, new independently validated outcomes, and accelerating employer adoption now point to a company that may be entering an inflection phase that the market doesn't yet seem to recognize (NASDAQ: DRIO)
Digital health has not been kind to investors. The last cycle produced too many companies that scaled too quickly, burned too much capital, and never proved that their solutions could actually bend the medical cost curve.…
Vegas Home Buyers Offers a Fast Cash Option for Homeowners Selling Houses in Las …
Image: https://www.abnewswire.com/upload/2025/11/f5ae9beaa45bcaf101121e1675b7ba18.jpg
Vegas Home Buyers [https://www.vegashb.com/], a family-owned real estate company, continues to provide homeowners across the Las Vegas valley with a straightforward, stress-free way to sell their homes fast for cash without repairs, agent fees, or long waiting periods. Founded by Kostika Xhurka, the company was created to give homeowners a simple option when a traditional sale doesn't fit their situation.
Selling a house in Las Vegas often involves showings, inspections,…
Cardiff Care Workers Missing Out on Uniform Tax Refunds
Many Cardiff care workers are missing out on tax relief for uniforms. Pie's HMRC-compliant PAYE tax rebate app makes it easy to reclaim money owed, simplifying the process and ensuring carers receive the refunds they deserve.
CARDIFF, United Kingdom - 17 November, 2025 - Thousands of Cardiff care workers are failing to claim tax relief on work-related uniforms, leaving hundreds of pounds unclaimed each year. Many carers are unaware they are…
Liverpool Small Businesses Go Digital to Beat Tax Deadlines
Pie Money Limited is a UK-based fintech company transforming how individuals and small businesses manage and file taxes. With real-time calculations, intuitive design, and HMRC-compliant filing, Pie helps users stay stress-free and fully compliant throughout the tax year.
LIVERPOOL, United Kingdom - 17 November, 2025 - Liverpool's small business community is embracing digital tax tools at record speed as Making Tax Digital (MTD) requirements continue to reshape the way SMEs manage…
More Releases for Uremic
US Atypical Hemolytic Uremic Syndrome Treatment Market Growth Outlook 2025-2031 …
The Global Atypical Hemolytic Uremic Syndrome (aHUS) Treatment Market is projected to grow from around USD 1.63 billion in 2024 to approximately USD 2.29 billion by 2029, registering a strong CAGR of 7.2% during the forecast period.
This growth is fueled by the increasing incidence and better recognition of this rare but life-threatening condition, along with the rising demand for targeted complement inhibitor therapies and advancements in diagnostics and personalized medicine.…
Uremic Pruritus Market is Expected to Reach USD 3.2 Billion by 2034
Uremic pruritus (UP), also known as chronic kidney disease-associated pruritus (CKD-aP), is a common and distressing symptom experienced by patients with end-stage renal disease (ESRD), particularly those on dialysis. It is characterized by persistent itching that significantly impacts sleep, mental health, and overall quality of life. Despite its prevalence, UP has historically been underdiagnosed and undertreated, often managed with non-specific therapies such as antihistamines and emollients.
Download Full PDF Sample Copy…
Atypical Hemolytic Uremic Syndrome Market Innovations, Key Players, and Growth O …
Atypical Hemolytic Uremic Syndrome (aHUS) is a rare and life-threatening condition characterized by hemolytic anemia, thrombocytopenia, and acute kidney failure. Unlike the more common typical HUS, which is typically caused by bacterial infections (e.g., E. coli), aHUS results from complement system dysfunction-the body's immune defense mechanism that, when overactive, leads to endothelial damage, microvascular thrombosis, and organ damage, primarily affecting the kidneys.
Download Full PDF Sample Copy of Market Report @…
Iptacopan A Comprehensive Forecast on the Accelerating Market Growth for Atypica …
[Las Vegas, United States] DelveInsight, a leader in healthcare research firm, has recently published an in-depth report on Iptacopan (Novartis) providing insights into the drug market landscape and market forecast of Iptacopan upto 2032. The report, titled "Iptacopan Market Size, Forecast, and Emerging Insight - 2032" is now available for review and analysis.
Are you interested in finding out the projected market size of Iptacopan in 2032? Iptacopan Market Forecast
https://www.delveinsight.com/report-store/iptacopan-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
…
Atypical Hemolytic Uremic Syndrome Treatment Market - Revolutionizing AHUS Care: …
Newark, New Castle, USA: The "Atypical Hemolytic Uremic Syndrome Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Atypical Hemolytic Uremic Syndrome Treatment Market: https://www.growthplusreports.com/report/atypical-hemolytic-uremic-syndrome-treatment-market/8948
This latest report…
Hemolytic Uremic Syndrome Treatment Market Statistical Forecast, Trade Analysis …
Newark, New Castle, USA - The latest report from Growth Plus Reports analyzes the production, potential applications, demand, major manufacturers, and SWOT analysis of the global Hemolytic Uremic Syndrome Treatment Market.
The Hemolytic Uremic Syndrome Treatment Market Report assists in determining the optimum distribution methods for certain products as well as possible markets for future product launches. The report also analyses the purchase and supply trends that influence the market's production…
